Alliance Pharma (GB:APH) has released an update.
Alliance Pharma PLC reports a robust first half of 2024 with revenues rising to £84.8 million, up 2.8% from the previous year, driven by a strong performance in its Kelo-Cote franchise. Despite a dip in Nizoral and Amberen sales, the company anticipates a recovery in the second half of the year, coupled with continued debt reduction and investment in marketing and innovation. CEO Nick Sedgwick is optimistic about the future, maintaining the Board’s expectation for the full year’s financial performance to align with the previous year’s.
For further insights into GB:APH stock, check out TipRanks’ Stock Analysis page.
